|
|
|
|
DiaMedBase ID |
|
DMPLt368 |
|
Medicinal Plant
|
|
Larrea tridentata |
|
Plant part(s)
|
|
Not available |
|
Objective |
|
To study the
ability of a pure compound isolated from the creosote bush (Larrea
tridentata) to lower plasma glucose concentration in two mouse models
of type 2 diabetes |
|
Journal Source
|
|
Eur
J Pharmacol.
1998; 346(1):77-79 |
|
Title
|
|
Masoprocol (nordihydroguaiaretic acid):
a new antihyperglycemic agent isolated from the creosote bush (Larrea
tridentata) |
|
Authors
|
|
Luo J, Chuang T, Cheung J, Quan J, Tsai
J, Sullivan C, Hector RF, Reed MJ, Meszaros K, King SR, Carlson TJ,
Reaven GM |
|
Address
|
|
Shaman Pharmaceuticals, South San Francisco, CA 94080-4812, USA |
|
Abstract
|
|
An ethnomedically-driven approach was
used to evaluate the ability of a pure compound isolated from the
creosote bush (Larrea tridentata) to lower plasma glucose
concentration in two mouse models of type 2 diabetes. The results
indicated that plasma glucose concentration fell approximately 8 mmol/l
in male C57BL/ks-db/db or C57BL/6J-ob/ob mice following the oral
administration of masoprocol (nordihydroguaiaretic acid), a well known
lipoxygenase inhibitor. The decline in plasma glucose concentration
following masoprocol treatment in the mice was achieved without any
change in plasma insulin concentration. In addition, oral glucose
tolerance improved and the ability of insulin to lower plasma glucose
concentrations was accentuated in masoprocol-treated db/db mice. These
data raise the possibility that masoprocol, or other lipoxygenase
inhibitors, represents a new approach to the pharmacological treatment
of Type 2 diabetes. |
|
Diseases |
|
Disease Link |
|